Drug profile · INN
technetium tc-99m succimer
NEPHROSCAN
technetium tc-99m succimer (NEPHROSCAN) is a alpha-2-macroglobulin binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — technetium tc-99m succimer
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
technetium tc-99m succimer (NEPHROSCAN) is a alpha-2-macroglobulin binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Alpha-2-macroglobulin binding agent
Primary target: Alpha-2-macroglobulin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is technetium tc-99m succimer?
technetium tc-99m succimer (NEPHROSCAN) is a alpha-2-macroglobulin binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for technetium tc-99m succimer?
NEPHROSCAN is a marketed brand name for technetium tc-99m succimer. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of technetium tc-99m succimer?
technetium tc-99m succimer has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.